{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022593","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.052220+00:00","generated_at":"2026-06-22T06:22:19.742150+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FibroGen Q3 loss of $91.7M; China roxadustat revenue up 29% YoY to $17.4M","bullets":["Total revenue $15.7M vs $156.0M in Q3 2021, which included $120M Astellas milestone","Net loss $91.7M ($0.98/sh) vs net income $49.8M ($0.54/sh) year ago","China roxadustat net sales $59.0M (incl. JDE); volume growth >80% vs Q3 2021","Completed MATTERHORN Phase 3 enrollment; topline data expected 1H 2023","Non-dilutive royalty monetization with NovaQuest provides $50M; cash target $380-410M YE 2022"],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022593","json":"https://secwatch.observer/filing/0000950170-22-022593.json","markdown":"https://secwatch.observer/filing/0000950170-22-022593.md","text":"https://secwatch.observer/filing/0000950170-22-022593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017022022593/0000950170-22-022593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017022022593/fgen-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T06:22:19.742150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5bc5e2a0831f2cdc5228a08975aac560267dd2f3","claim":"KYNTRA BIO, INC. reported the third quarter 2022 results: revenue $15.7 million, net income Net loss for the third quarter of 2022 was $91.7 million, or $0.98 net loss per basic and diluted share, EPS $0.98 net loss per basic and diluted share.","evidence_excerpt":"Total revenue for the third quarter of 2022 was $15.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017022022593/0000950170-22-022593-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter 2022"},{"label":"Revenue","value":"$15.7 million"},{"label":"Net income","value":"Net loss for the third quarter of 2022 was $91.7 million, or $0.98 net loss per basic and diluted share"},{"label":"EPS","value":"$0.98 net loss per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}